New hair loss treatment shows promises – paid volunteers needed to try it

The head is up!

A new possible treatment for androgenetic alopecia, also known as the male model bald, is boiling as a clinical test to prove its safety and effectiveness is developing.

The offers are annoying with regard to VDPHL01, a non-hormonal pill that shows promises of resetting the trouble-free hair of topical treatments and potentially serious hormonal medication side effects.

“I emphasize non-hormonal because the only oral treatment approved by the FDA for hair loss in the model has a hormone action mechanism and is associated with possible hormonal side effects such as erectile dysfunction, decreased libido and suicidal thoughts.” Neil Sadick told the post.

“Current options also often have high rates of discrimination as they can be messy and heavy to apply,” added Sadick, a clinical professor of dermatology at Weill Cornell Medical College.

There is no cure for androgenic alopecia even when it affects over 80 million Americans. The US Food and Drug Administration has approved Minoxidil and Topic Oral Finisteride (Propecia brand name) to treat hair loss.

Here’s what you need to know about VDPHL01.

What is VDPHL01?

VDPHL01 is Hawked by Veradermics, a New Haven -based biofarmic company Conn, who announced in December that it collected $ 75 million to fund the new trial.

Veradermics recently developed a “modified” minoxidil release tablet. Sadick refused to say if Vdphl01 contains minidil.

“The trial sponsor, Veradermics, is choosing not to disclose additional information about drug formulation at this time,” Sadick said.

“I can tell you that VDPHL01 has a unique profile unlike current FDA -approved treatments, which are associated with cardiac activity and unwanted sexual side effects,” he continued.

VDPHL01 is being studied as a once or twice-day pill. Sadick said preliminary phase 2 data revealed hair growth from two months after treatment. This “encouraging” data should be available in the coming months, he noted.

Veradermics expects to present an approval within a year from the end of his evidence – if they go well.

How does vdphl01 differ from other treatments?

Finasteride, which is sold as proscar or propecia, was approved by the FDA in the 90s. About 2.6 million people received Finasteride in 2022.

Pill prevents Testosterone from turning into another hormone called dihydrotestosterone (DHT). High DHT levels can make the hair glands shrink, leading to hair loss.

While finasteride reduces hair loss and promotes hair growth, is intended only for men and can cause erectile dysfunction, lowering the sex machine and depression, among other possible side effects.

The FDA, meanwhile, approved Minoxidil Oral in the 1970s to treat high blood pressure and topic minnoxidil in the 80s for hair loss.

Minoxidil increases blood flow to the hair glands, stimulating hair growth.

The side effects of OTC MED include scalp irritation, unwanted facial hair growth, chest pain, rapid heartbeat and dizziness.

When asked about the possible side effects of VDPHL01, Sadick said the conversation is “best between a study investigator and a possible judgment participant.”

Who can participate in the VDPHL01 trial?

Manhattan’s Sadick office, Sadick’s dermatology, is one of the 44 US countries involved in the 2/3 phase of VDPHL01 clinical test.

The goal is to register about 480 men in all study countries.

Sadick is looking for healthy men between 18 and 65 living in the NYC area and are experiencing the hair loss pattern. Applicants should be willing to keep their hair on the left a quarter -inch long throughout the study.

Those elected will be compensated for their participation, which includes 13 visits to Sadick’s dermatology over about 13 months. Registered patients will receive VDPHL01 or a placebo. Visit phlstudy.com or call (212) 772-7242 for more information or to register.

VDPHL01 is also being studied in women, with a phase 3 clinical test that is expected to begin later this year.